(Bloomberg) -- Moderna (NASDAQ: MRNA ) Inc.’s shares have dropped 50% this year as investors pulled back from Covid-19 healthcare stocks and staged a broader rotation out of growth names.
The biotech firm fell as much as 7.3% on Monday amid a broader market selloff and has erased more than $50 billion in value this year. Investors were concerned over the future revenue of Covid-19 vaccines and increasing competition in the space. The stock has lost more than 70% from its record closing high of $484.47 set in August 2021.
“Increasing competition and lack of visibility” about future sales has led to a loss of investor interest across the Covid-19 complex, Oppenheimer analyst Hartaj Singh, who has a market perform rating on Moderna, said in an interview.
Moderna soared during the pandemic as it raced to develop a Covid-19 vaccine. Its 143% gain last year made it the third-best stock in the S&P 500. It’s been on a breakneck ascent upward since debuting in 2018, skyrocketing by 434% in 2020.
By 2022, investors were looking ahead to future Covid-19 vaccine demand amid growing debate about the timing and need for boosters, as interest in pandemic-focused healthcare names waned. Impending Federal Reserve interest-rate hikes and the ongoing Russia-Ukraine war have also hurt sentiment across global stock markets. The S&P 500 Index has dropped 11% this year, while the Nasdaq 100 Index is down 17%.
“I think there’s a Covid loss of interest,” SVB Leerink analyst Daina Graybosch, who has a market perform rating on BioNTech and does not cover Moderna, said in an interview. “I see it across the board.”
©2022 Bloomberg L.P.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.